1190 A novel ‘2+1’bispecific T cell engager platform, enables enhanced anti-tumor activity with reduced risk of CRS

• Tengteng Li,
• Hui Yuwen,
• Bing Hou,
• Jay Mei,
• Bo Shan,
• Yijing Ren

Affiliations

Tengteng Li

1Antengene Corporation Co., Ltd, Shanghai, China

Hui Yuwen

2Antengene Corporation Co., Ltd, Shanghai, China

Bing Hou

1Antengene Corporation Co., Ltd, Shanghai, China

Jay Mei

3Antengene Corporation Co., Ltd, Shaoxing, Zhejiang, China

Bo Shan

3Antengene Corporation Co., Ltd, Shaoxing, Zhejiang, China

Yijing Ren

1Antengene Corporation Co., Ltd, Shanghai, China